Investor Contact: Jeremy Cohen
[email protected]
Media Contact: Nick Lucido
[email protected]
Covista Reports First Quarter Fiscal Year 2027 Results; Raises
Fiscal Year 2027 Revenue and Adjusted EPS Guidance
Total enrollment up 7.6% YoY
Revenue up 10.7% YoY
Diluted earnings per share $1.95; Adjusted EPS $2.19, growth of 25.1% YoY
Chief Financial Officer Robert Phelan announces planned retirement; will continue to serve until a
successor is named
FIRST QUARTER HIGHLIGHTS
• Total student enrollment of 104,713, up 7.6% year-over-year, achieved 13th straight quarter of
growth
• Revenue of $511.5 million, up 10.7% year-over-year
• Chamberlain University achieved 3rd straight quarter of total enrollment growth and achieved 17th
straight quarter of pre-licensure BSN total enrollment growth
• Walden University achieved 13th straight quarter of total enrollment growth, up 12.8% year-overyear, highest total enrollment in university history
• Medical and Veterinary delivered total enrollment growth of 3.5% year-over-year
• GAAP net income $67.4 million; adjusted EBITDA $131.2 million, up 17.1% year-over-year
CAPITAL ALLOCATION
• Repurchased $84 million of shares in the first quarter
• Net leverage of 0.5x as of Sep. 30, 2026
• Repriced our $510 million Term Loan B, reducing the interest rate margin by 25 basis points to
SOFR plus 2.00%
INCREASED FISCAL YEAR 2027 GUIDANCE
• Revenue in the range of $2,060 million to $2,095 million, or approximately 5.5% to 7% growth
year-over-year, and from a previous range of $2,050 million to $2,090 million
• Adjusted earnings per share in the range of $9.00 to $9.20, or approximately 9% to 11.5%
growth year-over-year, and from a previous range of $8.90 to $9.15
CHICAGO – October 29, 2026 /Businesswire/
Covista Inc. (NYSE: CVSA), America’s largest healthcare educator, today reported first quarter fiscal
year 2027 results (ended Sep. 30, 2026). This quarter, the Company launched Purpose at Scale, its
three-year strategy to train the next generation of healthcare professionals at industry-leading scale.
Purpose at Scale is underpinned by operational excellence, platform extension, employer integration
and a technology focus.
“Purpose at Scale is delivering and all four pillars of the strategy are contributing to our momentum.
Total enrollment grew for the 13th consecutive quarter, powering our double-digit revenue growth and
continued margin expansion. On that strength, we are raising our fiscal 2027 guidance,” said Steve
Beard, Chairman and Chief Executive Officer, Covista. “The demand behind our strategy is durable,
and Covista is critical infrastructure for American healthcare. We serve an urgent need in the
communities where care matters most, and by doing that well, we are strategically positioned to
create lasting value for our shareholders.”
Financial Highlights
Selected financial data for the three months ended Sept. 30, 2026:
• Revenue of $511.5 million increased 10.7% compared with the prior year
• Operating income of $98.0 million, compared with $85.5 million in the prior year;
adjusted operating income of $106.6 million, compared with $90.3 million in the prior year
• Net income of $67.4 million, compared with $61.8 million in the prior year;
adjusted net income of $75.8 million, compared with $64.9 million in the prior year
• Diluted earnings per share of $1.95, compared with $1.67 in the prior year;
adjusted earnings per share of $2.19, compared with $1.75 in the prior year
• Adjusted EBITDA of $131.2 million, compared with $112.0 million in the prior year;
adjusted EBITDA margin of 25.6%, compared with 24.2% in the prior year
Business Highlights
• Covista's strategic nursing collaboration with Advocate Health began enrolling students through
Chamberlain University in Wisconsin. Building on that successful launch, the relationship is
expanding to Chamberlain's three Chicago-area campuses.
• Chamberlain University opened its Cincinnati and Salt Lake City campuses. The Company also
announced it will open its 27th campus in Nashville, which is expected to begin classes in January
2027.
• Walden University launched four new programs this quarter. Programs introduced heading into
the 2026 academic year have already enrolled more than 2,000 students, demonstrating
Walden’s speed to market in high-demand fields.
• Covista released new analysis showing that students at Ross University School of Medicine and
American University of the Caribbean School of Medicine passed the United States Medical
Licensing Examination® (USMLE®) Step 1 on their first attempt at rates comparable to or higher
than U.S. MD students with similar MCAT scores in most score bands.1
• Covista’s performance and responsible business practices continued to earn national recognition,
including TIME’s America’s Growth Leaders 2027 and World’s Best Companies 2026, and
Newsweek’s America’s Greenest Companies 2027 and America’s Greatest Companies 2026.
Segment Highlights
Chamberlain
$ in millions
Revenue
Operating Income
Adj. Operating Income
Adj. EBITDA
Total Students (2)
Three Months Ended
September 30,
2026
2025
% Change
$192.4
$179.2
7.4%
$26.7
$25.6
4.4%
$26.7
$25.6
4.4%
$37.6
$35.1
7.1%
40,351
39,846
1.3%
• Total student enrollment increased 1.3% compared with the prior year, driven by growth in prelicensure nursing.
Walden
$ in millions
Revenue
Operating Income
Adj. Operating Income
Adj. EBITDA
Total Students (2)
Three Months Ended
September 30,
2026
2025
% Change
$216.7
$190.0
14.1%
$63.6
$53.3
19.5%
$65.0
$56.1
16.0%
$71.9
$61.9
16.1%
58,881
52,216
12.8%
• Total student enrollment increased 12.8% compared with the prior year, driven by growth in
healthcare and non-healthcare programs.
Medical and Veterinary
$ in millions
Revenue
Operating Income
Adj. Operating Income
Adj. EBITDA
Total Students (2)
Three Months Ended
September 30,
2026
2025
% Change
$102.5
$93.1
10.0%
$22.3
$16.7
33.0%
$22.3
$16.8
32.7%
$27.4
$21.4
27.9%
5,481
5,297
3.5%
• Total student enrollment increased 3.5% compared with the prior year, driven by growth in both
medical and veterinary.
Fiscal Year 2027 Outlook
Covista raised its revenue guidance for fiscal year 2027 from a range of $2,050 million to $2,090
million, or approximately 5% to 7% growth year-over-year, to a range of $2,060 million to $2,095
million, or approximately 5.5% to 7% growth year-over-year.
Covista also raised its adjusted earnings per share guidance from a range of $8.90 to $9.15, or
approximately 8% to 11% growth year-over-year, to a range of $9.00 to $9.20, or approximately 9%
to 11.5% growth year-over-year.
Management Update
Chief Financial Officer Robert Phelan has decided to retire from Covista after nearly seven years, as
part of a planned transition. He will remain in this role until a successor is named, with no change in
responsibilities. He will support the incoming Chief Financial Officer through a transition period. An
active search is underway.
Conference Call and Webcast Information
Covista will hold a conference call to discuss its first quarter fiscal year 2027 results today at 4:00
p.m. CT (5:00 p.m. ET).
The call can be accessed by dialing +1 877-407-6184 (U.S. participants) or +1 201-389-0877
(international participants) and stating “Covista earnings call” or by using conference
ID:13762351. The call will be simulcast through the Covista investor relations website at:
https://investors.covista.com/.
Covista will archive a replay of the call for 30 days. To access the replay, dial +1 877-660-6853 (U.S.)
or +1 201-612-7415 (international), conference ID: 13762351, or visit the Covista investor relations
website.
About Covista
Covista (NYSE: CVSA) is America's largest healthcare educator, serving 100,000 students and
supported by a community of 400,000 alumni across five accredited institutions. Through
personalized, tech-enabled education powered by 10,000 faculty and colleagues, Covista expands
access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale.
Covista is the parent company of American University of the Caribbean School of Medicine,
Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary
Medicine and Walden University. For more information, visit Covista.com and follow us on LinkedIn,
Instagram and YouTube.
Cautionary Disclosure Regarding Forward-Looking Statements
Certain statements contained in this release are forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of
future events based on certain assumptions and include any statement that does not directly relate to
any historical or current fact, which includes statements regarding Covista’s future growth. Forwardlooking statements generally can be identified by the use of forward-looking terminology such as
“future,” “believe,” “project,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “may,” “will,”
“would,” “could,” “can,” “continue,” “preliminary,” “potential,” “range,” and similar terms. These
forward-looking statements are subject to risk and uncertainties that could cause actual results to
differ materially from those described in the statements. Important factors that could cause actual
results to differ materially from the expectations expressed or implied by our forward-looking
statements are disclosed in Item 1A. “Risk Factors,” of our Annual Report on Form 10-K. You should
evaluate forward-looking statements in the context of these risks and uncertainties and are cautioned
to not place undue reliance on such forward-looking statements. We caution you that these factors
may not contain all of the factors that are important to you. We cannot assure you that we will realize
the results, performance or developments we expect or anticipate or, even if substantially realized,
that they will result in the consequences or affect us or our operations in the way we expect. All
forward-looking statements are based on information available to us as of the date any such
statements are made, and Covista assumes no obligation to publicly update or revise its forwardlooking statements even if experience or future changes make it clear that any projected results
expressed or implied therein will not be realized, except as required by law.
A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on
a forward-looking basis without unreasonable effort due to the uncertainty of special items that may
be incurred in the future, although these special items could be material to Covista's results in
accordance with GAAP.
1.
Comparison using university and AAMC data. Data is based on students who matriculated between
2021-2023 and sat for the USMLE Step 1 as of August 2026. Not all matriculants sat for the
USMLE Step 1 exam. Students must successfully matriculate, complete the Medical Sciences
curriculum and pass a school approved Medical Sciences Comprehensive Exam to sit for the
USMLE Step 1 exam.
Represents total students attending sessions during each institution’s most recent enrollment
period in Q1 FY 2027 and Q1 FY 2026.
Covista Inc.
Consolidated Balance Sheets
(unaudited)
(in thousands)
September 30,
2026
Assets:
Current assets:
Cash and cash equivalents
Restricted cash
Accounts and financing receivables, net
Prepaid expenses and other current assets
Total current assets
Noncurrent assets:
Property and equipment, net
Operating lease assets
Intangible assets, net
Goodwill
Other assets, net
Total noncurrent assets
Total assets
Liabilities and shareholders' equity:
Current liabilities:
Accounts payable
Accrued payroll and benefits
Accrued liabilities
Deferred revenue
Current operating lease liabilities
Current portion of long-term debt
Total current liabilities
Noncurrent liabilities:
Long-term debt
Long-term operating lease liabilities
Deferred income taxes
Other liabilities
Total noncurrent liabilities
Total liabilities
Commitments and contingencies
Total shareholders' equity
Total liabilities and shareholders' equity
$
$
$
222,223
2,336
241,469
86,542
552,570
324,706
197,511
752,860
961,262
139,364
2,375,703
2,928,273
96,383
57,720
126,214
365,096
33,984
5,100
684,497
June 30,
2026
$
$
$
495,131
219,374
69,320
38,308
822,133
1,506,630
$
1,421,643
2,928,273
406,316
1,438
169,561
75,126
652,441
302,649
204,364
754,254
961,262
137,738
2,360,267
3,012,708
124,763
78,669
94,364
259,125
34,799
5,100
596,820
657,750
207,846
61,782
42,325
969,703
1,566,523
$
1,446,185
3,012,708
Covista Inc.
Consolidated Statements of Income
(unaudited)
(in thousands, except per share data)
Revenue
Operating cost and expense:
Cost of educational services
Student services and administrative expense
Restructuring expense
Total operating cost and expense
Operating income
Interest expense
Other income, net
Income from continuing operations before income taxes
Provision for income taxes
Income from continuing operations
Discontinued operations:
(Loss) income from discontinued operations before income taxes
Benefit from income taxes
(Loss) income from discontinued operations
Net income and comprehensive income
Earnings (loss) per share:
Basic:
Continuing operations
Discontinued operations
Total basic earnings per share
Diluted:
Continuing operations
Discontinued operations
Total diluted earnings per share
Weighted-average shares outstanding:
Basic shares
Diluted shares
$
Three Months Ended
September 30,
2026
2025
511,534
$
462,288
220,759
192,585
163
413,507
98,027
(9,944)
1,416
89,499
(18,017)
71,482
200,767
175,734
310
376,811
85,477
(11,090)
2,486
76,873
(15,811)
61,062
$
(5,420)
1,365
(4,055)
67,427
$
747
23
770
61,832
$
$
$
2.11
(0.12)
1.99
$
$
$
1.69
0.02
1.71
$
$
$
2.07
(0.12)
1.95
$
$
$
1.65
0.02
1.67
33,951
34,573
36,111
37,057
Covista Inc.
Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
Three Months Ended
September 30,
2026
2025
Operating activities:
Net income
Loss (income) from discontinued operations
Income from continuing operations
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation
Amortization of operating lease assets
Depreciation
Amortization of acquired intangible assets
Amortization and write-off of debt discount and issuance costs
Provision for credit losses
Deferred income taxes
Loss on disposals and impairments of property and equipment
Loss (gain) on investments
Changes in assets and liabilities:
Accounts and financing receivables
Prepaid expenses and other current assets
Cloud computing implementation assets
Accounts payable
Accrued payroll and benefits
Accrued liabilities
Deferred revenue
Operating lease liabilities
Other assets and liabilities
Net cash provided by operating activities-continuing operations
Net cash used in operating activities-discontinued operations
Net cash provided by operating activities
Investing activities:
Capital expenditures
Proceeds from sales of marketable securities
Purchases of marketable securities
Net cash used in investing activities
Financing activities:
Proceeds from exercise of stock options
Employee taxes paid on withholding shares
Proceeds from stock issued under Colleague Stock Purchase Plan
Repurchases of common stock for treasury
Repayments under long-term debt obligations
Payment of debt issuance costs
Net cash used in financing activities
Net (decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
$
$
67,427
4,055
71,482
$
61,832
(770)
61,062
8,181
7,018
10,862
1,394
660
22,402
8,798
—
218
8,293
7,216
10,296
2,805
1,145
14,883
54,413
2
(680)
(94,219)
(10,788)
(3,292)
(13,536)
(20,886)
13,025
107,928
10,548
(5,524)
114,271
(233)
114,038
(62,690)
(29,841)
(4,812)
1,378
(24,359)
(12,287)
109,082
(4,317)
(960)
130,629
(80)
130,549
(37,592)
—
—
(37,592)
(16,023)
100
(100)
(16,023)
—
(16,203)
564
(81,002)
(163,000)
—
(259,641)
(183,195)
407,754
224,559
131
(39,119)
411
(7,595)
—
(3,333)
(49,505)
65,021
201,164
266,185
$
Covista Inc.
Segment Revenue
(unaudited)
(in thousands)
Three Months Ended
September 30,
Increase/(Decrease)
2025
$
%
2026
Revenue:
Chamberlain
Walden
Medical and Veterinary
Consolidated
$
$
192,400
216,673
102,461
511,534
$
$
179,201
189,960
93,127
462,288
$
$
13,199
26,713
9,334
49,246
7.4 %
14.1 %
10.0 %
10.7 %
Covista Inc.
Non-GAAP Financial Measures and Reconciliations
We believe that certain non-GAAP financial measures provide investors with useful supplemental information
regarding the underlying business trends and performance of Covista’s ongoing operations as seen through the eyes
of management and are useful for period-over-period comparisons. We use these supplemental non-GAAP financial
measures internally in our assessment of performance and budgeting process. However, these non-GAAP financial
measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in
accordance with GAAP. The following are non-GAAP financial measures used in the subsequent GAAP to nonGAAP reconciliation tables:
Adjusted net income (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted
for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt
extinguishment, debt modification costs, U.S. tax benefit due to an increase in foreign-derived income, and loss
(income) from discontinued operations.
Adjusted earnings per share (most comparable GAAP measure: diluted earnings per share) – Measure of Covista’s
diluted earnings per share adjusted for restructuring expense, amortization of acquired intangible assets, strategic
advisory costs, loss on debt extinguishment, debt modification costs, U.S. tax benefit due to an increase in foreignderived income, and loss (income) from discontinued operations.
Adjusted operating income (most comparable GAAP measure: operating income) – Measure of Covista’s operating
income adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, and
debt modification costs.
Adjusted EBITDA (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for
loss (income) from discontinued operations, interest expense, other income, net, provision for income taxes,
depreciation, amortization of acquired intangible assets, amortization of cloud computing implementation assets,
stock-based compensation, restructuring expense, strategic advisory costs, and debt modification costs. Provision for
income taxes, interest expense, and other income, net are not recorded at the reportable segments, and therefore, the
segment adjusted EBITDA reconciliations begin with adjusted operating income.
Free cash flow (most comparable GAAP measure: net cash provided by operating activities-continuing operations)
– Defined as net cash provided by operating activities-continuing operations less capital expenditures.
Net debt – Defined as total long-term debt principal less cash and cash equivalents.
Net leverage – Defined as net debt divided by adjusted EBITDA.
A description of special items in our non-GAAP financial measures described above are as follows:
• Restructuring expense primarily related to workforce reductions and prior real estate consolidations at
Covista’s home office. We do not include normal, recurring, cash operating expenses in our restructuring
expense.
• Amortization of acquired intangible assets.
• Amortization of cloud computing implementation assets.
• Strategic advisory costs related to expanding capabilities and bringing new capacities to market to further
enhance our strategic position. We do not include normal, recurring, cash operating expenses in our strategic
advisory costs.
• Loss on debt extinguishment related to the amendment of the Revolver.
• Debt modification costs related to refinancing our Term Loan B.
• U.S. tax benefit due to an increase in foreign-derived income.
• Loss (income) from discontinued operations includes activity from ongoing litigation costs and settlements
related to prior divestitures.
Covista Inc.
Adjusted Operating Income
(unaudited)
(in thousands)
Three Months Ended
September 30,
Increase/(Decrease)
2025
$
%
2026
Chamberlain:
Operating income
Adjusted operating income
Operating margin
Adjusted operating margin
Walden:
Operating income
Amortization of acquired intangible assets
Adjusted operating income
$
$
26,730
$
26,730
$
13.9 %
13.9 %
25,608
$
25,608
$
14.3 %
14.3 %
1,122
1,122
4.4 %
4.4 %
$
63,649
1,394
65,043
53,269
2,805
56,074
10,380
(1,411)
8,969
19.5 %
5,523
(44)
5,479
33.0 %
12,550
(147)
(1,411)
4,547
756
16,295
14.7 %
$
Operating margin
Adjusted operating margin
Medical and Veterinary:
Operating income
Restructuring expense
Adjusted operating income
$
29.4 %
30.0 %
$
$
Operating margin
Adjusted operating margin
Covista(1):
Operating income (GAAP)
Restructuring expense
Amortization of acquired intangible assets
Strategic advisory costs
Debt modification costs
Adjusted operating income (non-GAAP)
$
22,251
—
22,251
$
98,027
163
1,394
6,231
756
106,571
Operating margin (GAAP)
19.2 %
Adjusted operating margin (non-GAAP)
20.8 %
(1)
Consolidated results include Home Office activities not allocated to segments.
$
16.0 %
28.0 %
29.5 %
$
$
21.7 %
21.7 %
$
$
16,728
44
16,772
$
$
32.7 %
18.0 %
18.0 %
$
$
85,477
310
2,805
1,684
—
90,276
18.5 %
19.5 %
$
$
18.1 %
Covista Inc.
Adjusted EBITDA
(unaudited)
(in thousands)
Three Months Ended
September 30,
Increase/(Decrease)
2025
$
%
2026
Chamberlain:
Adjusted operating income (GAAP)
Depreciation
Amortization of cloud computing implementation assets
Stock-based compensation
Adjusted EBITDA (non-GAAP)
$
$
Adjusted EBITDA margin (non-GAAP)
Walden:
Adjusted operating income (GAAP)
Depreciation
Amortization of cloud computing implementation assets
Stock-based compensation
Adjusted EBITDA (non-GAAP)
Adjusted EBITDA margin (non-GAAP)
Medical and Veterinary:
Adjusted operating income (GAAP)
Depreciation
Amortization of cloud computing implementation assets
Stock-based compensation
Adjusted EBITDA (non-GAAP)
$
$
$
$
Adjusted EBITDA margin (non-GAAP)
Covista(1):
Net income (GAAP)
Loss (income) from discontinued operations
Interest expense
Other income, net
Provision for income taxes
Depreciation and amortization
Stock-based compensation
Restructuring expense
Strategic advisory costs
Debt modification costs
Adjusted EBITDA (non-GAAP)
26,730
6,094
2,386
2,372
37,582
$
$
$
Adjusted EBITDA margin (non-GAAP)
(1)
Consolidated results include Home Office activities not allocated to segments.
$
$
1,122
719
859
(198)
2,502
4.4 %
7.1 %
19.5 %
19.6 %
65,043 $
1,784
2,253
2,782
71,862 $
33.2 %
56,074 $
1,940
1,204
2,653
61,871 $
32.6 %
8,969
(156)
1,049
129
9,991
16.0 %
22,251
2,823
931
1,390
27,395
16,772
2,820
411
1,410
21,413
5,479
3
520
(20)
5,982
32.7 %
5,595
4,825
(1,146)
1,070
2,206
1,583
(112)
(147)
4,547
756
19,177
9.0 %
$
$
26.7 %
$
25,608
5,375
1,527
2,570
35,080
67,427
4,055
9,944
(1,416)
18,017
17,826
8,181
163
6,231
756
131,184
25.6 %
$
$
16.1 %
27.9 %
23.0 %
$
$
61,832
(770)
11,090
(2,486)
15,811
16,243
8,293
310
1,684
—
112,007
24.2 %
$
$
17.1 %
Covista Inc.
Adjusted Earnings
(unaudited)
(in thousands, except per share data)
Three Months Ended
September 30,
2026
2025
Net income (GAAP)
$
67,427
$
61,832
Restructuring expense
163
310
Amortization of acquired intangible assets
1,394
2,805
Strategic advisory costs
6,231
1,684
Loss on debt extinguishment and debt modification costs
756
295
U.S. tax benefit due to an increase in foreign-derived income
(2,031)
—
Income tax impact on non-GAAP adjustments(1)
(2,152)
(1,224)
Loss (income) from discontinued operations
4,055
(770)
Adjusted net income (non-GAAP)
$
75,843
$
64,932
(1)
Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our
GAAP financial statements.
Three Months Ended
September 30,
2026
2025
Diluted earnings per share (GAAP)
Effect on diluted earnings per share:
Restructuring expense
Amortization of acquired intangible assets
Strategic advisory costs
Loss on debt extinguishment and debt modification costs
U.S. tax benefit due to an increase in foreign-derived income
Income tax impact on non-GAAP adjustments(1)
Loss (income) from discontinued operations
Adjusted earnings per share (non-GAAP)
$
1.95
0.00
0.04
0.18
0.02
(0.06)
(0.06)
0.12
2.19
34,573
$
1.67
0.01
0.08
0.05
0.01
(0.03)
(0.02)
1.75
37,057
$
$
Diluted shares
Note: May not sum due to rounding.
(1)
Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our
GAAP financial statements.
Covista Inc.
Free Cash Flow
(unaudited)
(in thousands)
FY26
Q1
Net cash provided by operating
activities-continuing operations (GAAP)
Capital expenditures
Free cash flow (non-GAAP)
$
$
374,796 $
(55,936)
318,860 $
FY26
Q2
Twelve Months Ended
FY26
Q3
427,890 $
(59,880)
368,010 $
406,335 $
(69,872)
336,463 $
FY26
Q4
470,796 $
(77,696)
393,100 $
FY27
Q1
454,438
(99,265)
355,173
Covista Inc.
Net Leverage
(unaudited)
(in thousands)
Twelve Months Ended
September 30, 2026
Covista:
Net income (GAAP)
Loss from discontinued operations
Interest expense
Other income, net
Provision for income taxes
Depreciation and amortization
Stock-based compensation
Restructuring expense
Strategic advisory costs
Debt modification costs
Adjusted EBITDA (non-GAAP)
Total long-term debt principal
Less: Cash and cash equivalents
Net debt (non-GAAP)
Net leverage (non-GAAP)
$
$
$
$
257,161
20,634
44,289
(6,108)
79,950
73,836
41,104
6,182
23,109
756
540,913
September 30, 2026
510,000
(222,223)
287,777
0.5x